Oleclumab

Oleclumab
Monoclonal antibody
Type	?
Source	Human
Target	5'-nucleotidase NT5E
Clinical data
Other names	MEDI9447
ATC code	none;
Identifiers
CAS Number	1803176-05-7;
ChemSpider	none;
UNII	5CRY01URYQ;
KEGG	D10963;
Chemical and physical data
Formula	C6348H9826N1710O1998S40
Molar mass	143350.81 g·mol−1

Oleclumab (INN;^[1] development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.^[2]

This drug was developed by MedImmune/AstraZeneca.^[3]

References

^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
^ ClinicalTrial.gov for Oleclumab
^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[WHOList116-1] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).

[2] ClinicalTrial.gov for Oleclumab

[3] Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.

[1]

[2]

[3]